Alector rises on achieving target enrollment for dementia treatment trial
27/10/2023 13:52
** Shares of drug developer Alector ALEC.O rise ~5% to
$5.53 premarket
** Company says it has achieved enrollment target in the
late-stage trial for its investigational treatment latozinemab
in patients with a type of dementia
** The trial enrolled 101 patients with frontotemporal
dementia due to a progranulin gene mutation
** Latozinemab is being developed in collaboration with GSK
GSK.L
** The treatment is a human monoclonal antibody designed to
modulate progranulin, a key regulator of immune activity in the
brain with genetic links to multiple neurodegenerative disorders
** Up to last close, stock down ~43% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))